surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Company profile
Ticker
SRDX
Exchange
Website
CEO
Gary Maharaj
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Surmodics IVD, Inc. • NorMedix, Inc. • Creagh Medical Limited • SurModics MD, LLC • Surmodics MD Operations, LLC • Surmodics Coatings, LLC • Surmodics Coatings Mfg, LLC • Surmodics Holdings, LLC • Surmodics Shared Services, LLC • Vetex Medical Limited ...
IRS number
411356149
SRDX stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
12 Feb 24
10-Q
2024 Q1
Quarterly report
1 Feb 24
8-K
Updates Fiscal Year 2024 Financial Guidance
1 Feb 24
DEF 14A
Definitive proxy
18 Dec 23
DEFA14A
Additional proxy soliciting materials
18 Dec 23
10-K
2023 FY
Annual report
22 Nov 23
8-K
Results of Operations and Financial Condition
8 Nov 23
10-Q
2023 Q3
Quarterly report
2 Aug 23
8-K
Updates Fiscal Year 2023 Financial Guidance
2 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
26 Jul 23
Transcripts
SRDX
Earnings call transcript
2024 Q1
1 Feb 24
SRDX
Earnings call transcript
2023 Q4
8 Nov 23
SRDX
Earnings call transcript
2023 Q3
2 Aug 23
SRDX
Earnings call transcript
2023 Q2
26 Apr 23
SRDX
Earnings call transcript
2023 Q1
6 Feb 23
SRDX
Earnings call transcript
2022 Q4
13 Nov 22
SRDX
Earnings call transcript
2022 Q3
27 Jul 22
SRDX
Earnings call transcript
2022 Q2
27 Apr 22
SRDX
Earnings call transcript
2023 Q2
26 Apr 22
SRDX
Earnings call transcript
2022 Q1
3 Feb 22
Latest ownership filings
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
JOSE H BEDOYA
12 Feb 24
4
DAVID DANTZKER
12 Feb 24
4
RONALD B KALICH SR
12 Feb 24
4
SUSAN E KNIGHT
12 Feb 24
4
Lisa Wipperman Heine
12 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
SC 13G/A
Trigran Investments, Inc.
9 Feb 24
4
SUSAN E KNIGHT
7 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 41.42 mm | 41.42 mm | 41.42 mm | 41.42 mm | 41.42 mm | 41.42 mm |
Cash burn (monthly) | 1.05 mm | (no burn) | 929.67 k | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 6.30 mm | n/a | 5.56 mm | n/a | n/a | n/a |
Cash remaining | 35.12 mm | n/a | 35.86 mm | n/a | n/a | n/a |
Runway (months of cash) | 33.3 | n/a | 38.6 | n/a | n/a | n/a |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 107 |
Opened positions | 8 |
Closed positions | 21 |
Increased positions | 37 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 374.64 bn |
Total shares | 14.37 mm |
Total puts | 66.80 k |
Total calls | 2.70 k |
Total put/call ratio | 24.7 |
Largest owners | Shares | Value |
---|---|---|
Trigran Investments | 2.36 mm | $73.84 bn |
Soleus Capital Management | 1.34 mm | $41.86 bn |
Millennium Management | 1.02 mm | $31.79 bn |
BLK Blackrock | 1.01 mm | $31.48 bn |
Vanguard | 826.53 k | $25.88 bn |
Soleus Capital Master Fund | 775.31 k | $0.00 |
Trigran Investments | 710.26 k | $0.00 |
Renaissance Technologies | 591.14 k | $18.46 bn |
WELLINGTON TRUST Co N A | 589.71 k | $28.40 mm |
Disciplined Growth Investors | 407.08 k | $12.75 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Feb 24 | Jose H Bedoya | Common Stock | Grant | Acquire A | No | No | 0 | 1,803 | 0.00 | 28,957 |
8 Feb 24 | Jose H Bedoya | Common Stock | Payment of exercise | Dispose F | No | No | 31.89 | 2,954 | 94.20 k | 27,154 |
8 Feb 24 | Jose H Bedoya | Common Stock | Option exercise | Acquire M | No | No | 23.95 | 3,932 | 94.17 k | 30,108 |
8 Feb 24 | Jose H Bedoya | Stock Option Common Stock | Grant | Acquire A | No | No | 31.89 | 3,853 | 122.87 k | 3,853 |
8 Feb 24 | Jose H Bedoya | Stock Option Common Stock | Option exercise | Dispose M | No | No | 23.95 | 3,932 | 94.17 k | 0 |
8 Feb 24 | Dantzker David | Common Stock | Grant | Acquire A | No | No | 0 | 1,803 | 0.00 | 39,124 |
8 Feb 24 | Dantzker David | Stock Option Common Stock | Grant | Acquire A | No | No | 31.89 | 3,853 | 122.87 k | 3,853 |
8 Feb 24 | Kalich Ronald B SR | Common Stock | Grant | Acquire A | No | No | 0 | 1,803 | 0.00 | 38,278 |
8 Feb 24 | Kalich Ronald B SR | Stock Option Common Stock | Grant | Acquire A | No | No | 31.89 | 3,853 | 122.87 k | 3,853 |
8 Feb 24 | Susan E Knight | Common Stock | Grant | Acquire A | No | No | 0 | 1,944 | 0.00 | 35,148 |
News
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
1 Feb 24
Needham Maintains Buy on Surmodics, Raises Price Target to $47
1 Feb 24
Surmodics Q1 Adjusted EPS $0.00 May Not Be Comparable To $(0.30) Estimate, Sales $30.55M Beat $29.64M Estimate
1 Feb 24
Earnings Scheduled For February 1, 2024
1 Feb 24
A Preview Of Surmodics's Earnings
31 Jan 24
Press releases
Surmodics to Participate in Upcoming Investor Conferences in March and April
27 Feb 24
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
1 Feb 24
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
22 Jan 24
Surmodics to Host Virtual Annual Meeting of Shareholders
16 Jan 24
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
16 Jan 24